News and Trends 23 May 2023 Vicore reports new data from idiopathic pulmonary fibrosis study Vicore Pharma Holding AB (publ), has announced an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function. The disease is currently considered to be incurable and […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2023 Swedish company develops first effective treatment for hypothyroidism Prolevi Bio has developed a technology intended to help the 10 to 20% of people who don’t respond to current treatments for underactive thyroid glands. The company has developed a modified release thyroid hormone tablet formulation, mimicking the natural hormone release cycles. In addition, the treatment will be tailored according to each patient’s needs using […] May 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2023 Alzheimer’s drugs could result from immune brain cell discovery A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also […] May 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 21 Apr 2023Beyond Biotech podcast 42 This week, we’re talking about the upcoming Lund Spring Symposium with Claes Wahlestedt, Leonard M. Miller professor and director of the Center for Therapeutic Innovation (CTI) and associate dean for therapeutic innovation at the University of Miami Miller School of Medicine; about Meet2Win with Lucia Robert, CEO of MATWIN which stages the event; and then […] April 21, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2023 Wound treatment boost from new color-changing dressing A nanocellulose wound dressing that can reveal early signs of infection without interfering with the healing process has been developed by researchers at Linköping University, Sweden. The study, published in Materials Today Bio, is another step on the road to a new type of wound care. The skin is the largest organ of the human […] April 19, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2023 Swedish bacterial resistance study could pave road to new antibiotics A species of ordinary gut bacteria flourishes when the intestinal flora is knocked out by a course of antibiotics. Since the bacteria are naturally resistant to many antibiotics, this can cause problems. A study at Lund University in Sweden now shows how two molecular mechanisms can work together to make the bacterium extra resistant. “Using […] April 17, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Metabolism of RNA linked to leukemia Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits in cancer. RNA splicing is […] March 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Calliditas shares rise as phase 3 endpoints met in kidney disease trial Swedish company Calliditas Therapeutics AB has announced positive topline results from the global, randomized, double-blind, placebo-controlled phase 3 clinical trial investigating the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas share prices rose 30% in the aftermath of the announcement. IgAN, or Berger’s disease, is […] March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 New event set to take place in Swedish biotech hub A new event, which will include presentations by Nobel laureates, is set to showcase the best of pharmacology. The Lund Spring Symposium, which takes place from May 24 to 26 at the Palaestra et Odeum in Lund, Sweden, aims to raise the profile of pharmacology as a cross-functional discipline in the 21st Century and to […] February 21, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Genetic study reveals high variation in T-cell receptor genes T-cells are central in the protection against infections and cancer. With the help of TCRs (T-cell receptors), cells recognize foreign invaders and tumor cells. “It was previously unknown how variable human TCR genes are,” said Gunilla Karlsson Hedestam, professor at the department of microbiology, tumor and cell biology at Karolinska Institutet in Sweden, and the […] February 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 Antibody candidate for treating serious liver disease There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […] February 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Active Biotech trial confirms eye treatment safety Active Biotech has announced the completion of the phase I clinical study testing the safety and tolerability of its newly-developed laquinimod eye drop formulation in healthy subjects. According to the results, the eye drop was safe and well tolerated both at single ascending doses and after repeated doses for up to 21 days. No serious […] January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email